INTRODUCTION
Anti-remodeling drugs reduce fracture risk by altering both structural and material bone properties [1] . Suppressed bone remodeling enhances bone structure through increases in bone volume and maintenance of trabecular architecture [2, 3] . At the material level, remodeling suppression increases average tissue mineralization and tissue density homogeneity [4] . Biomechanically, these structural and material changes enhance whole bone strength and stiffness, yet increased mineralization is also negatively correlated to toughness [5] [6] [7] . A greater understanding of the net balance among structural and material alterations that occur with anti-remodeling treatment is necessary.
We and others have documented that bisphosphonate administration at 5x the clinical dose for treatment of post-menopausal osteoporosis, increases trabecular bone volume, mineralization, ultimate load and stiffness in dog vertebra [8, 9] . However, remodeling suppression to levels produced by these doses also significantly increases microdamage accumulation and decreases bone toughness [8, 9] . These previous studies were designed to examine the role of remodeling suppression on microdamage and biomechanical properties, rather than the effects of individual bisphosphonate treatments, which have demonstrated anti-fracture efficacy [10] . The results have raised some concerns about long-term antiremodeling therapies [11, 12] , but the applicability of these data to clinical situations remains unclear because the bisphosphonate doses were 5-to 6-times the clinical dose used for treatment of post-menopausal osteoporosis. Although the degree of remodeling suppression in these dog studies was similar to that of post-menopausal women [13] , it may represent over-suppression in a non-osteoporotic dog model that has slower bone turnover compared to post-menopausal women. It is possible that the microdamage and toughness changes in the dog model are specific to the high doses used in these previous studies.
The objective of this study was to quantify the changes in bone remodeling, microdamage accumulation, and biomechanical properties following 1-year treatment with bisphosphonate doses equivalent to those used for prevention/treatment of post-menopausal osteoporosis.
Our hypothesis was these clinical treatment doses would allow significant increases in microdamage accumulation and reductions in toughness due to suppression of bone remodeling. To test this hypothesis, skeletally mature female beagle dogs were treated daily for 1 year with either risedronate or alendronate at the clinical treatment dose (0.10 and 0.20 mg/kg/day p.o, respectively), as well as lower and higher doses so that dose-response effects for damage accumulation and toughness could also be determined. Density, geometry, mineralization, remodeling, microdamage, and biomechanical properties of vertebral bone were quantified. 82
MATERIALS AND METHODS

Animals
Eighty-four skeletally mature female beagles (1.3 ± 0.02 years old) were purchased from Marshall Farms USA (North Rose, NY). Upon arrival, lateral X-rays of all dogs were obtained to confirm skeletal maturity (closed proximal tibia and lumbar vertebra growth plates). Animals were housed two per cage in environmentally controlled rooms at Indiana University School of Medicine's AALAC accredited facility and provided standard dog chow and water. All procedures were approved prior to the study by the Indiana University School of Medicine Animal Care and Use Committee.
Experimental Design
Following two weeks of acclimatization, animals were assigned to treatment groups (n=12/group) by matching body weights. All dogs were treated daily for 1-year with oral doses of vehicle (saline), risedronate sodium (Procter and Gamble Pharmaceuticals, Inc) or alendronate sodium (Merck and Co., Inc). Alendronate doses (0.10, 0.20, and 1.00 mg/kg/day) were chosen to correspond with clinical doses used for post-menopausal osteoporosis. The lower two doses are equivalent (on a mg/kg basis) to the preventative (5 mg) and therapeutic (10 mg) doses of alendronate. Based on the ratios of in vivo potency
100
(1:2) and clinical dose levels (2:1), dose-equivalents of risedronate were administered at 101 doses of 0.05, 0.10, and 0.50 mg/kg/day. Both risedronate and alendronate were dissolved in 102 saline and administered to the dogs orally with a syringe. Vehicle-treated animals received 1 103 ml/kg/day of saline. Dosing was performed each morning after an overnight fast and at least 104 2 hours prior to feeding.
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Prior to necropsy, animals were injected with calcein (0.20 mL/kg, IV) using a 2-12-2-5 106 labeling schedule (9 animals per group) or a 2-5-2-5 (3 animals per group). The shorter 107 interlabel duration was due to a scheduling error. Animals were euthanized by intravenous 108 administration of sodium pentobarbital (0.22mg/kg Beuthanasia-D Special). After death, 109 thoracic and lumbar vertebrae were dissected and saved for analyses. The ninth thoracic and 110 fourth lumbar vertebrae were separately wrapped in saline-soaked gauze and frozen (-20ºC 
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Biomechanical Testing
178
The biomechanical properties of fourth lumbar vertebrae were quantified using a 179 servohydraulic testing system (MTS 810, MTS Corporation). Following densitometry, 180 vertebral height was measured using digital calipers (Starrett #721; L.S. Starrett Co).
181
Compression to failure was carried out on saline soaked specimens using displacement 182 control mode (20 mm/min). Load vs displacement curves were recorded using a HP-7090 
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The reason for this is unclear but we believe it is not likely a true biological effect given that 369 other skeletal sites in these dogs, such as the femoral neck, show increased BV/TV 370 comparable to the dose-equivalent of ALN (data not shown).
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The results of this study should be considered in light of various limitations. Use of 372 intact, non-ovariectomized beagle dogs may limit the translation of these results to high vddck (•V1 vdliclt), ANOVA ttl!:i111&IJ gr med 10 dccmnin dlfl crtoca 11 doteeqm•1knls(no do6e--tqUiv1kn1 ciffn-ctK for tbeet 'ari1bJell). ,., . ..
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